Comedian Alan Carr chucks the chocolate to help children with neuroblastoma

To mark International Childhood Cancer Day (15 Feb 2020), comedian and chocoholic Alan Carr has made a pledge to give up his favourite treat and raise money for research into neuroblastoma, a rare childhood cancer. 

Alan Carr, comedian and celebrity patron of Neuroblastoma UK, is supporting the charity’s Great Give It Up this March and said, “Neuroblastoma is a horrible cancer which mostly affects children. I love a cheeky bit of chocolate and it’ll be a huge challenge for me to give it up! But it’s nowhere near as big a challenge as what these children go through.

“Children with neuroblastoma need treatment which can make them so sick that they have to give up their favourite food too. But they don’t have a choice. Please join me this March and make your Great Give It Up pledge today to help fund vital research into neuroblastoma.”

How it works

It’s simple - choose something to give up during March and and make your #GreatGiveItUp pledge at www.neuroblastoma.org.uk/great-give-it-up It could be anything from giving up chocolate like Alan, laying off the lattes, cutting out crisps to making it a meat-free March.

By donating the money you’d save to Neuroblastoma UK, you’ll be funding vital research to help deliver new, effective and kinder treatments for children with neuroblastoma.

Your donations will fund much-needed research to improve treatments and one day, find a cure for neuroblastoma.

• £2 - or your daily coffee - could pay for a glass petri dish to help researchers grow and study cells, to understand the causes of neuroblastoma
• £25 - or your weekly lunch - could buy a pack of microscope slides, enabling scientists to examine neuroblastoma cells in minute detail.
• £50 - or filling up the car with petrol - could pay for equipment to help researchers grow neuroblastoma cells and study possible treatment of the disease.
• £100 - or your weekly takeaway during March - could help pay for a DNA extraction kit, enabling researchers to develop personalised treatment for children with neuroblastoma.

ENDS